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EVIDENCE BASED NEURO-ONCOLOGY
Stereotactic Radiosurgery for pituitary adenomas: A review of literature
Kaynat Siddiqui1, Saqib Kamran Bakhshi2, Muhammad Shahzad Shamim3

Abstract
Stereotactic radiosurgery (SRS) is a choice of treatment for
pituitary adenomas (PA), particularly for residual or
recurrent disease, apart from surgery. It has a progression
free survival and endocrine remission rate comparable to
surgery, with fewer side eﬀects, making it an ideal tool for
dealing with PA. In this review, we have discussed the role
of SRS for primary as well as post-operative residual/
recurrent PA, and have assessed its safety and outcomes.

significantly lower morbidity as compared to surgery.1 Due
to relatively small risk of complications such as
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Introduction
Trans-sphenoidal resection has been the mainstay in
treatment of pituitary adenomas (PA). Managing residual
or recurrent tumours, however, has been a dilemma for
most surgeons. Treatment options include watchful
observation for small non-growing tumours, and reoperation or radiotherapy for growing lesions.1 The
alteration in bony anatomy after the first surgery, local
fibrosis/scarring, higher risk of CSF leaks and the chance of
incomplete resection make second attempt at approaching
these tumours via trans-sphenoidal route challenging.2
Factors influencing choice of treatment include secretory
nature of tumour, cavernous sinus invasion and extent of
compression on optic chiasm.2
Non-surgical treatment modalities for managing nonfunctioning pituitary adenoma include conventional
fractionated external beam radiotherapy (EBRT) and
stereotactic radiosurgery (SRS).3 Progressive development
and improvement in SRS during the last decade, have
made it one of the ideal choices for managing patients
medically unfit for surgery, for tumours left behind after
incomplete resection, and to restrict the growth of residual
tumours showing disease progression.3 SRS works by
disintegrating DNA strands directly as a result of radiation,
as well as by causing the release of free radicals, and by
progressively obliterating vascular supply to the tumour.4
With a dose of 12-18 Gy, growth restriction can be achieved
in up to 90% cases according to some studies, with
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Figure-1: MRI brain, coronal section, delayed image T1 post-contrast sequence,
of a 58 years old male, showing a giant contrast enhancing sellar and
suprasellar lesion, which is displacing the floor of the 3rd ventricle,
and is partially encasing both the internal carotid arteries.

Figure-2: MRI brain, coronal section, delayed image T1 post-contrast sequence, of
the same patient after trans-sphenoidal resection. The previously seen
bulk of the tumour has been maximally resected with small residual
tumour, and the mass eﬀect has been reduced. Histopathology was
reported as pituitary adenoma. The patient was advised stereotactic
radiosurgery for the residual disease.
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deterioration of vision, hypopituitarism and injury to
hypothalamus, and extensively published literature
supporting its utility, SRS is slowly gaining popularity in
treating pituitary adenomas.5 In this study, we have
conducted an extensive literature search to identify studies
on the role of SRS for pituitary adenomas, and summarise
the findings. SRS in this review will include gamma knife
radiosurgery as well as cyberknife radiosurgery.

Review of evidence
In one of the earliest comprehensive retrospective studies
conducted by Castinetti et al., it was concluded that SRS is
eﬀective in causing remission of secretory pituitary
adenomas in more than 40% cases after a mean follow-up
of 8 years (96 months) from surgery.6 They reviewed 76
patients who had received gamma knife radiosurgery as a
primary treatment or as an adjunct to surgery, and
reported the risk of developing hypopituitarism to be the
main adverse eﬀect of SRS, among all patients in their
cohort.6 Park et al., conducted the first large scale study on
the outcomes of SRS in 125 patients with non-functioning
pituitary adenomas, over a 22-year period.7 One hundred
and ten patients (88%) had residual disease after 1 or more
surgeries. The median radiation dose was 13 Gy, and
median target volume was 3.5 cm3.7 They reported a
reduction in tumour size in 66 (53%) patients, no change
in size in 46 (37%) patients and tumour progression in 13
(10.4%) patients.7 At 1-, 5- and 10-year follow-up after SRS,
the tumour control rates were 99%, 94% and 76%
respectively.7 In a similar study published a year later, 140
patients who had gamma knife surgery were
retrospectively reviewed for long-term outcomes by Starke
et al.8 Thirteen of these patients had received radiosurgery
as a primary treatment, while 123 had undergone at least
1 surgery before SRS.8 The mean tumour volume was
5.6 cm3 and the mean marginal dose was 18 Gy.8 They
reported a better 10-year progression-free survival at 87%
as compared to Part et al., and a higher radiation dose
might have been the reason.7,8 The most common
complication was delayed hypopituitarism, seen in 30.3%
patients.8
The role of SRS without surgery in treating pituitary
adenomas was studied in 41 patients who could not be
operated due to comorbidities or patients’ choice, by Lee
et al.9 They reported a 10-year tumour control rate of 85%
at a median tumour margin dose of 12 Gy, and concluded
that SRS can be employed as the primary treatment
modality for treating non-functioning pituitary adenomas
with good tumour controls, and minimal risks.9 Hasegawa
et al., published a retrospective case series of 16 patients
with non-functioning pituitary adenomas, who had
undergone gamma knife radiosurgery alone, without
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surgery.10 The median tumour size was 2.0 cm3 and the
median radiation dose was 15 Gy. Fifteen patients had
shown tumour regression and one had a stable disease, at
a median follow-up of 98 months.10 Only 1 patient in their
series had hypopituitarism due to pituitary apoplexy prior
to SRS, requiring hormone replacement therapy. They had
concluded SRS to be a safe treatment option for nonfunctioning pituitary adenomas, though because of smaller
sample size, they had cautioned against the possibility of
long-term hypopituitarism, radiation-induced neoplasm
and visual deterioration due to optic neuropathy.10
Wu et al., conducted a case control study on 75 patients
with acromegaly, and compared the endocrine and surgical
outcomes of primary gamma-knife surgery with SRS after
partial tumour resection.11 They concluded no significant
diﬀerence between the two groups in terms of local disease
control, endocrine remission and tumour recurrence, and
recommended SRS for all patients with residual or recurrent
growth-hormone secreting adenomas, as well as a primary
treatment option for patients who are high-risk for
surgery.11 Kotecha et al., conducted a systematic review
and meta-analysis on the outcomes and adverse eﬀects of
SRS for non-functioning pituitary adenomas.12 They
included 35 studies (2671 patients) in their review. They
recommended SRS as a safe treatment option, but also
proposed that more data will be needed to put forward
definitive guidelines, as all the available evidence
comprised of retrospective studies.12 In another recent
systematic review and meta-analysis regarding residual or
recurrent pituitary adenomas, 26 articles (2315 patients)
were analyzed.1 The review proved eﬃcacy of SRS in
residual and recurrent pituitary adenomas, irrespective of
the secretory nature, with fewer side eﬀects.1 However, the
absence of any randomized control trial was an important
limitation of this review as well.1

Conclusion
The available evidence supports the eﬀectiveness of SRS in
managing residual/recurrent, functional and nonfunctional pituitary adenomas alike, with progression-free
survival of more than 80% at 10-years. Due to absence of
any randomized control trials, application of SRS as a firstline treatment/replacement of surgery in pituitary
adenomas is still debatable, and requires more data.
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